SCHEDULE 13G/A: Armistice Capital and Steven Boyd Disclose 8.47% Stake in Ironwood Pharmaceuticals

Armistice Capital, LLC and Steven Boyd have disclosed a beneficial ownership of 8.47% of Ironwood Pharmaceuticals Inc.'s Class A common stock, totaling 13,700,000 shares, as of March 31, 2025.

Summary

• Armistice Capital, LLC and Steven Boyd (collectively, the "Reporting Persons") have filed an Amendment No. 2 to Schedule 13G regarding their beneficial ownership in Ironwood Pharmaceuticals Inc.
• The filing reports beneficial ownership of 13,700,000 shares of Class A common stock, representing 8.47% of the outstanding shares.
• This percentage is based on 161,809,432 shares outstanding as of February 28, 2025, as reported in Ironwood Pharmaceuticals' Form 10-K filed on March 31, 2025.
• Armistice Capital, LLC, a Delaware entity, acts as the investment manager for Armistice Capital Master Fund Ltd., which is the direct holder of the shares.
• Steven Boyd, a U.S. citizen, is the managing member of Armistice Capital, LLC and is deemed to beneficially own the shares.
• The filing indicates that the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 6

Explanation: The filing of a Schedule 13G indicates a significant beneficial ownership by an institutional investor, which can be perceived as a positive signal of confidence in the company. However, the document itself is purely factual and does not contain forward-looking statements or performance metrics to assess a strong sentiment.

Positives

• Armistice Capital, LLC and Steven Boyd have acquired a significant 8.47% stake in Ironwood Pharmaceuticals Inc., which can be interpreted by the market as a vote of confidence in the company's prospects.

Future Outlook

NA

Industry Context

This filing indicates a significant investment by an institutional fund in a pharmaceutical company, a common occurrence in the healthcare sector where specialized funds often take substantial positions based on drug pipelines, market potential, or strategic outlook.

Stakeholder Impact

• Shareholders may view this significant stake by Armistice Capital and Steven Boyd as a vote of confidence in Ironwood Pharmaceuticals Inc., potentially leading to increased investor interest.

Key Dates

Keywords

Ironwood Pharmaceuticals, Armistice Capital, Steven Boyd, Schedule 13G, Beneficial Ownership, Class A common stock, Institutional Investor, Pharmaceuticals, Healthcare